Hepatitis B and C epidemiology in selected population groups in the EU/EEA

With the Covid-19 outbreak having caused significant disruption to healthcare services, including those for hepatitis C, this webinar was organised to discuss how services have been affected in different areas across the country and explore how hepatitis C services can most effectively be re-established as we emerge from the early phase of the outbreak. The webinar featured contributions from the following speakers: • Mark Gillyon-Powell - Head of Programme, HCV Elimination, NHS England & NHS Improvement • Dr Steve Ryder - Chair, HCV Action and Clinical Lead, Nottingham Hepatitis C ODN

This 2020 update on drug-related infectious diseases from the EMCDDA (European Monitoring Centre for Drugs and Drug Addiction) aims to provide a comprehensive overview of the current situation with regard to the epidemiological picture of drug-related infectious diseases in Europe up to January 2020. It highlights some recent innovative responses to the problem and argues that early diagnosis through testing as well as improving links to treatment and care are crucial steps towards reaching global health goals.